• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    77 Biggest Movers From Yesterday

    6/1/22 5:02:22 AM ET
    $ACOR
    $AMR
    $ANF
    $ANGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Coal Mining
    Energy
    Get the next $ACOR alert in real time by email

    Gainers

    • TherapeuticsMD, Inc. (NASDAQ:TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners.
    • JanOne Inc. (NASDAQ:JAN) gained 66.5% to close at $3.73 after the company announced it sold GeoTraq to SPYR Technologies in a $13.5 million transaction.
    • Mullen Automotive, Inc. (NASDAQ:MULN) jumped 44.9% to settle at $1.40 after the company announced results of its solid-state polymer battery testing with the Battery Innovation Center in Indiana.
    • Studio City International Holdings Limited (NASDAQ:MSC) gained 43.3% to close at $3.21.
    • CatchMark Timber Trust, Inc. (NYSE:CTT) shares climbed 42.1% to close at $11.79 after the company and PotlatchDeltic announced they have entered into a definitive agreement to combine in an all-stock transaction.
    • Xcel Brands, Inc. (NASDAQ:XELB) gained 36.7% to settle at $1.49 after the company announced WHP will purchase a controlling 70% interest in fashion brand Isaac Mizrahi.
    • DURECT Corporation (NASDAQ:DRRX) jumped 32.1% to settle at $0.55. Durect, last month, posted a Q1 net loss of $10.8 million.
    • ReShape Lifesciences Inc. (NASDAQ:RSLS) surged 28.7% to close at $1.0105.
    • Houston American Energy Corp. (NYSE:HUSA) gained 27.4% to settle at $4.79. Houston American Energy increased interest in the Colombian project. According to Stocktwits, Houston American Energy was the number one trending stock for the day.
    • Stealth BioTherapeutics Corp (NASDAQ:MITO) surged 26.8% to close at $0.2690.
    • mCloud Technologies Corp. (NASDAQ:MCLD) jumped 25.7% to close at $3.77.
    • BlackSky Technology Inc. (NASDAQ:BKSY) surged 24.8% to close at $3.27.
    • Versus Systems Inc. (NASDAQ:VS) jumped 24% to close at $0.63.
    • OpGen, Inc. (NASDAQ:OPGN) gained 23.2% to close at $0.69.
    • Pop Culture Group Co., Ltd (NASDAQ:CPOP) surged 21.9% to settle at $1.28.
    • MoonLake Immunotherapeutics (NASDAQ:MLTX) jumped 21.2% to close at $7.73.
    • RISE Education Cayman Ltd (NASDAQ:REDU) climbed 21.2% to close at $1.37.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) gained 21.2% to settle at $0.5091.
    • MicroStrategy Incorporated (NASDAQ:MSTR) surged 20.7% to settle at $264.69 in sympathy with the price of Bitcoin and Ethereum.
    • Biotricity, Inc. (NASDAQ:BTCY) gained 20.6% to settle at $1.23.
    • Eargo, Inc. (NASDAQ:EAR) jumped 20.2% to close at $1.55 after Nasdaq confirmed continued listing of the stock.
    • Summit Therapeutics Inc. (NASDAQ:SMMT) gained 19.8% to close at $1.33. Summit Therapeutics, last month, posted a Q1 loss of $0.22 per share.
    • Gogoro Inc. (NASDAQ:GGR) rose 19.3% to close at $5.01.
    • 180 Life Sciences Corp. (NASDAQ:ATNF) jumped 18.3% to settle at $1.62 after the company announced it has initiated preliminary consultations with UK and US regulatory agencies on a pathway for a Dupuytren's disease therapy.
    • Rockwell Medical, Inc. (NASDAQ:RMTI) gained 18% to settle at $1.64. Rockwell Medical entered into securities purchase agreements with Armistice Capital Master Fund Ltd to purchase $15 million of common stock and warrants.
    • Esports Entertainment Group, Inc. (NASDAQ:GMBL) gained 17.7% to close at $0.46. HC Wainwright & Co. maintained Esports Entertainment with a Buy and lowered the price target from $6 to $1.5.
    • Angion Biomedica Corp. (NASDAQ:ANGN) jumped 17.3% to close at $1.76. Angion Biomedica, last month, posted a Q1 loss of $0.48 per share.
    • NexImmune, Inc. (NASDAQ:NEXI) gained 16.9% to settle at $2.28. NexImmune, last month, posted a Q1 loss of $0.66 per share.
    • Skylight Health Group Inc. (NASDAQ:SLHG) jumped 16.9% to close at $0.8301. Skylight Health Group, last month, posted Q1 loss from continuing operations of $7.6 million.
    • Full Truck Alliance Co. Ltd. (NYSE:YMM) climbed 16.7% to close at $6.93.
    • Sesen Bio, Inc. (NASDAQ:SESN) gained 16.7% to close at $0.6129.
    • Sigma Labs, Inc. (NASDAQ:SASI) rose 16.7% to settle at $1.3999.
    • KE Holdings Inc. (NYSE:BEKE) rose 16.6% to settle at $13.40 after the company announced better-than-expected Q1 sales results.
    • Talaris Therapeutics, Inc. (NASDAQ:TALS) gained 16.4% to close at $8.61.
    • Ikena Oncology, Inc. (NASDAQ:IKNA) jumped 16.1% to close at $3.90. Ikena Oncology, last month, posted a Q1 loss of $0.47 per share.
    • Grupo Aval Acciones y Valores S.A. (NYSE:AVAL) gained 16.1% to close at $4.91.
    • WiSA Technologies, Inc. (NASDAQ:WISA) jumped 15.3% to close at $0.8221.
    • Marine Petroleum Trust (NASDAQ:MARPS) rose 13.4% to close at $8.82.
    • Sangoma Technologies Corporation (NASDAQ:SANG) gained 12.9% to settle at $9.31.
    • Performance Shipping Inc. (NASDAQ:PSHG) rose 11.9% to close at $0.7420. Performance Shipping shares dipped around 64% on Friday after the company announced the pricing of an underwritten public offering of 7,620,000 units at $1.05 per unit.
    • Venator Materials PLC (NYSE:VNTR) gained 11.4% to close at $2.54.
    • Pineapple Energy Inc. (NASDAQ:PEGY) climbed 10.7% to close at $13.06. Pineapple Holdings recently posted a Q1 loss of $0.58 per share.
    • Borr Drilling Limited (NYSE:BORR) shares rose 10.7% to settle at $5.57 after the company reported preliminary results for its first quarter.
    • Grab Holdings Limited (NASDAQ:GRAB) gained 10.4% to close at $2.66 after Bernstein upgraded the stock from Market Perform to Outperform.
    • New Oriental Education & Technology Group Inc. (NYSE:EDU) shares climbed 9.6% to close at $13.06.
    • Bakkt Holdings, Inc. (NYSE:BKKT) gained 7.1% to close at $2.85 in sympathy with the price of Bitcoin and Ethereum.
    • Indonesia Energy Corporation Limited (NYSE:INDO) gained 6.4% to close at $16.73 after gaining 6% on Friday.

     


    Losers

    • Icosavax, Inc. (NASDAQ:ICVX) dropped 33.6% to close at $6.79. Icosavax recently posted a Q1 loss of $0.60 per share.
    • Outlook Therapeutics, Inc. (NASDAQ:OTLK) dipped 32% to settle at $1.15. Outlook Therapeutics said that the FDA has requested additional information in order to complete filing of company’s BLA for ONS-5010/ LYTENAVA.
    • PDS Biotechnology Corporation (NASDAQ:PDSB) shares declined 27.1% to close at $3.92. PDS Biotech announced expansion of its Versatile-002 clinical trial into Europe.
    • Elevation Oncology, Inc. (NASDAQ:ELEV) shares fell 25.4% to close at $2.26. Elevation Oncology recently announced the FDA granted Fast Track designation to seribantumab for the tumor-agnostic treatment of advanced solid tumors that harbor NRG1 gene fusions.
    • Gold Fields Limited (NYSE:GFI) fell 23.4% to close at $9.34 on Tuesday after the company announced it will acquire Yamana Gold for $6.7 billion.
    • PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) fell 23.3% to close at $11.76.
    • PropertyGuru Limited (NYSE:PGRU) fell 23% to close at $5.59. PropertyGuru recently reported Q1 sales of S$28.2 million.
    • JE Cleantech Holdings Limited (NASDAQ:JCSE) fell 22.6% to close at $11.60.
    • Innovid Corp. (NYSE:CTV) dropped 22% to close at $3.80.
    • MSP Recovery, Inc. (NASDAQ:MSPR) fell 21.8% to settle at $1.36.
    • Perma-Pipe International Holdings, Inc. (NASDAQ:PPIH) dropped 21.2% to close at $11.73.
    • Immix Biopharma, Inc. (NASDAQ:IMMX) fell 20.2% to close at $2.14.
    • SIGA Technologies, Inc. (NASDAQ:SIGA) dropped 20% to settle at $10.94.
    • Farmmi, Inc. (NASDAQ:FAMI) fell 18.1% to close at $1.27 following effect of 1:25 reverse stock split.
    • Bright Green Corporation (NASDAQ:BGXX) dipped 17.8% to close at $5.08.
    • Myriad Genetics, Inc. (NASDAQ:MYGN) declined 16.8% to settle at $19.24.
    • BioSig Technologies, Inc. (NASDAQ:BSGM) fell 16.3% to close at $0.9874.
    • Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) dipped 15.6% to settle at $2.82.
    • Frontline Ltd. (NYSE:FRO) shares dropped 15.3% to close at $9.68 after gaining 5% on Friday.
    • LexinFintech Holdings Ltd. (NASDAQ:LX) declined 14.8% to settle at $2.02 after the company reported unaudited results for the first quarter.
    • Kirkland's, Inc. (NASDAQ:KIRK) dropped 14.6% to close at $5.79 as the company reported a first-quarter FY22 sales decline of 16.4% to $103.29 million, missing the consensus of $110.46 million.
    • TG Therapeutics, Inc. (NASDAQ:TGTX) fell 14.5% to close at $4.42. TG Therapeutics announced FDA extension of BLA PDUFA date for ublituximab to treat patients with RMS.
    • Celldex Therapeutics, Inc. (NASDAQ:CLDX) dipped 14.5% to settle at $23.52.
    • BuzzFeed, Inc. (NASDAQ:BZFD) fell 14.4% to close at $3.5950.
    • Purple Innovation, Inc. (NASDAQ:PRPL) dropped 14% to close at $5.18.
    • Evolve Transition Infrastructure LP (NYSE:SNMP) declined 13.8% to close at $0.5690.
    • Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares fell 11.6% to close at $2.21. Needham maintained Avadel Pharmaceuticals with a Buy and lowered the price target from $14 to $6.
    • Alpha Metallurgical Resources, Inc. (NYSE:AMR) dropped 9.8% to close at $161.74.
    • Abercrombie & Fitch Co. (NYSE:ANF) dropped 9.4% to close at $20.44.
    • NetScout Systems, Inc. (NASDAQ:NTCT) declined 8.8% to close at $34.33 after Piper Sandler downgraded the stock from Neutral to Underweight and lowered its price target from $35 to $33.
    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AMR
    $ANF
    $ANGN

    CompanyDatePrice TargetRatingAnalyst
    Alpha Metallurgical Resources Inc.
    $AMR
    2/4/2026$203.00Buy → Neutral
    B. Riley Securities
    KE Holdings Inc
    $BEKE
    2/3/2026$19.00Buy → Neutral
    Goldman
    New Oriental Education & Technology Group Inc. Sponsored ADR r
    $EDU
    1/28/2026Hold → Buy
    HSBC Securities
    Strategy Inc
    $MSTR
    1/27/2026$213.00Overweight
    Cantor Fitzgerald
    Abercrombie & Fitch Company
    $ANF
    1/21/2026$135.00Neutral → Buy
    Citigroup
    Grab Holdings Limited
    $GRAB
    1/16/2026$6.20Hold → Buy
    HSBC Securities
    Full Truck Alliance Co. Ltd.
    $YMM
    1/12/2026Neutral → Underweight
    Analyst
    Frontline Plc
    $FRO
    1/12/2026Neutral → Buy
    Clarksons Platou
    More analyst ratings

    $ACOR
    $AMR
    $ANF
    $ANGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy

    12/29/21 7:23:57 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AMR
    $ANF
    $ANGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alpha Metallurgical Resources downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Alpha Metallurgical Resources from Buy to Neutral and set a new price target of $203.00

    2/4/26 8:27:05 AM ET
    $AMR
    Coal Mining
    Energy

    KE Holdings downgraded by Goldman with a new price target

    Goldman downgraded KE Holdings from Buy to Neutral and set a new price target of $19.00

    2/3/26 6:53:05 AM ET
    $BEKE
    Real Estate
    Finance

    New Oriental Education & Technology upgraded by HSBC Securities

    HSBC Securities upgraded New Oriental Education & Technology from Hold to Buy

    1/28/26 3:01:34 PM ET
    $EDU
    Other Consumer Services
    Real Estate

    $ACOR
    $AMR
    $ANF
    $ANGN
    SEC Filings

    View All

    SEC Form DEF 14A filed by OpGen Inc.

    DEF 14A - OPGEN INC (0001293818) (Filer)

    2/6/26 1:05:05 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form 6-K filed by KE Holdings Inc

    6-K - KE Holdings Inc. (0001809587) (Filer)

    2/6/26 6:01:43 AM ET
    $BEKE
    Real Estate
    Finance

    SEC Form 144 filed by Abercrombie & Fitch Company

    144 - ABERCROMBIE & FITCH CO /DE/ (0001018840) (Subject)

    2/5/26 4:24:49 PM ET
    $ANF
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ACOR
    $AMR
    $ANF
    $ANGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thompson Tommy G bought $14,031 worth of shares (8,400 units at $1.67), increasing direct ownership by 57% to 23,179 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    12/29/25 4:23:31 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman D Loren Robert W bought $94,908 worth of shares (81,466 units at $1.17), increasing direct ownership by 13% to 687,297 units (SEC Form 4)

    4 - XCel Brands, Inc. (0001083220) (Issuer)

    12/19/25 12:42:34 PM ET
    $XELB
    Multi-Sector Companies
    Miscellaneous

    Director Courtis Kenneth S. bought $1,693,441 worth of shares (9,000 units at $188.16), increasing direct ownership by 1% to 816,537 units (SEC Form 4)

    4 - Alpha Metallurgical Resources, Inc. (0001704715) (Issuer)

    12/17/25 4:53:28 PM ET
    $AMR
    Coal Mining
    Energy

    $ACOR
    $AMR
    $ANF
    $ANGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abercrombie & Fitch Co. to Report Fourth Quarter and Full Year 2025 Results on March 4, 2026

    NEW ALBANY, Ohio, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Abercrombie & Fitch Co. (NYSE:ANF) will host its quarterly earnings conference call for all interested parties on Wednesday, March 4, 2026, at 8:30 a.m. ET. A press release detailing the company's fourth quarter and full year results is expected to be issued shortly after 7:30 a.m. ET. In addition, a presentation of the fourth quarter and full year results will be available on the company's website at approximately 7:30 a.m. ET. Conference Call:To access the conference call by phone, participants will need to register to obtain a dial-in phone number and an access code. Register for the call using this link.  Webcast:To listen to a live w

    2/6/26 8:00:00 AM ET
    $ANF
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

    NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in San Diego, California. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We are pleased to share data at this year's ACTRIMS annual meeting, including updates from the ENABLE real world study evaluating patients with RMS on BRIUMVI. Our presentations reflect our continued focus on advancing the clinical understanding of

    2/6/26 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AMR
    $ANF
    $ANGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Baes Nicholas decreased direct ownership by 5% to 101,023 units (SEC Form 5)

    5 - Bakkt, Inc. (0001820302) (Issuer)

    2/6/26 7:02:42 PM ET
    $BKKT
    Finance: Consumer Services
    Finance

    Chief Executive Officer Horowitz Fran sold $6,920,168 worth of shares (67,031 units at $103.24), decreasing direct ownership by 17% to 338,272 units (SEC Form 4)

    4 - ABERCROMBIE & FITCH CO /DE/ (0001018840) (Issuer)

    2/6/26 4:55:25 PM ET
    $ANF
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Director Mccamish Mark Anthony gifted 67,025 units of Ordinary Shares and received a gift of 67,025 units of Ordinary Shares (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    2/6/26 4:10:10 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AMR
    $ANF
    $ANGN
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AMR
    $ANF
    $ANGN
    Financials

    Live finance-specific insights

    View All

    Abercrombie & Fitch Co. to Report Fourth Quarter and Full Year 2025 Results on March 4, 2026

    NEW ALBANY, Ohio, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Abercrombie & Fitch Co. (NYSE:ANF) will host its quarterly earnings conference call for all interested parties on Wednesday, March 4, 2026, at 8:30 a.m. ET. A press release detailing the company's fourth quarter and full year results is expected to be issued shortly after 7:30 a.m. ET. In addition, a presentation of the fourth quarter and full year results will be available on the company's website at approximately 7:30 a.m. ET. Conference Call:To access the conference call by phone, participants will need to register to obtain a dial-in phone number and an access code. Register for the call using this link.  Webcast:To listen to a live w

    2/6/26 8:00:00 AM ET
    $ANF
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    NETSCOUT Reports Third Quarter Fiscal Year 2026 Financial Results

    Quarterly Results Exceed Top and Bottom-Line Expectations Company Raises Midpoint of Fiscal Year 2026 Top- and Bottom-line Outlook Ranges NETSCOUT SYSTEMS, INC. (NASDAQ:NTCT), a leading provider of enterprise network observability, carrier service assurance, cybersecurity, and Distributed-Denial-of-Service (DDoS) protection solutions, today announced financial results for its third quarter ended December 31, 2025. Remarks by Anil Singhal, NETSCOUT's President & Chief Executive Officer: "Our Q3 fiscal year 2026 revenue and earnings results were ahead of expectations. This performance was enhanced by certain product orders and service renewals originally anticipated for the fourth qua

    2/5/26 7:30:00 AM ET
    $NTCT
    EDP Services
    Technology

    $ACOR
    $AMR
    $ANF
    $ANGN
    Leadership Updates

    Live Leadership Updates

    View All

    Bakkt Agrees to Acquire Distributed Technologies Research Ltd.

    - Acquisition advances Bakkt's global stablecoin settlement and programmable payments strategy- Company to operate as "Bakkt, Inc." effective January 22, 2026- Investor Day scheduled for March 17, 2026 at the New York Stock Exchange NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Bakkt Holdings, Inc. ("Bakkt" or the "Company") (NYSE:BKKT) today announced that it has agreed to acquire Distributed Technologies Research Ltd. ("DTR"), a global stablecoin payment infrastructure provider. Pursuant to the definitive agreement, and as consideration for DTR, Bakkt will issue shares of its Class A common stock representing 31.5% of the "Bakkt Share Number," as defined in the previously announced Coope

    1/12/26 8:00:00 AM ET
    $BKKT
    Finance: Consumer Services
    Finance

    Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

    ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. "We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value

    1/6/26 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangoma Technologies Corporation Announces Voting Results from its Annual General and Special Meeting of Shareholders

    Sangoma Technologies Corporation (TSX:STC, NASDAQ:SANG) ("Sangoma" or the "Company"), a trusted industry leader uniquely offering businesses a choice of on-premises, cloud-based, or hybrid Communications as a Service solutions, announced today the results of voting at its annual general and special meeting of shareholders held on December 16, 2025 (the "Meeting"). Each of the seven nominees listed in the Company's management information circular dated November 5, 2025 provided in connection with the Meeting were elected as directors of the Company. Sangoma received proxies and virtual votes at the Meeting as set out below: Nominee Votes For % of Votes For Votes Withheld %

    12/16/25 1:30:00 PM ET
    $SANG
    Computer Software: Programming Data Processing
    Technology

    $ACOR
    $AMR
    $ANF
    $ANGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Full Truck Alliance Co. Ltd.

    SC 13G/A - Full Truck Alliance Co. Ltd. (0001838413) (Subject)

    12/3/24 4:30:33 PM ET
    $YMM
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by DURECT Corporation

    SC 13G/A - DURECT CORP (0001082038) (Subject)

    11/19/24 5:10:25 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care